Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019August 16, 2022 Alterity Therapeutics

Prana Biotechnology BSC Presntation 20180107 FINAL

2019

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Alterity Therapeutics to Participate in the Sachs Associates 6^th Annual Neuroscience Innovation Forum

January 3, 2023May 23, 2023

Prana – ANA Abstract Submission NLP

October 17, 2016August 16, 2022

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

September 20, 2022May 23, 2023

Recent Posts

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
Alterity Therapeutics to Present at MST Financial Webinar
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
Webcast Presentation on New Data from the bioMUSE Natural History Study

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065